Determination of enantiomer impurity in Bortezomib lyo injection formulation by using normal-phase liquid chromatography

Abstract Background A highly stereo-specific liquid chromatographic technique was built up and authenticated to quantify the (1S,2R-enantiomer) impurity in Bortezomib lyo injection formulation. The separation was achieved on Chiral Pak ID-3 (3 μm, 4.6 × 250 mm) column (“amylose-based 3-chlorophenylc...

Full description

Bibliographic Details
Main Authors: Sanni Babu Najana, Hari Babu Bollikolla
Format: Article
Language:English
Published: SpringerOpen 2021-01-01
Series:Future Journal of Pharmaceutical Sciences
Subjects:
Online Access:https://doi.org/10.1186/s43094-020-00157-4
id doaj-7247f9f6ceb34b27ad4404cbf82eba2d
record_format Article
spelling doaj-7247f9f6ceb34b27ad4404cbf82eba2d2021-01-10T12:54:00ZengSpringerOpenFuture Journal of Pharmaceutical Sciences2314-72532021-01-017111110.1186/s43094-020-00157-4Determination of enantiomer impurity in Bortezomib lyo injection formulation by using normal-phase liquid chromatographySanni Babu Najana0Hari Babu Bollikolla1Department of Chemistry, Acharya Nagarjuna UniversityDepartment of Chemistry, Acharya Nagarjuna UniversityAbstract Background A highly stereo-specific liquid chromatographic technique was built up and authenticated to quantify the (1S,2R-enantiomer) impurity in Bortezomib lyo injection formulation. The separation was achieved on Chiral Pak ID-3 (3 μm, 4.6 × 250 mm) column (“amylose-based 3-chlorophenylcarbamate” chiral stationary phase) through a movable segment consisting of n-heptane, 2-propanol, ethyl alcohol, and TFA (82:15:3:0.1, v/v/v/v) at a flow rate of 0.6 mL/min. Column temperature preserved 25 °C, injection level 20 μL, sample cooler temperature ambient, and detection wavelength 270 nm. Results The retention time of (1S,2R-enantiomer) impurity and Bortezomib was determined 10.57 and 17.98 min, respectively. The resolution between (1S,2R-enantiomer) impurity and Bortezomib was found to be 4.2. The acceptance limit of the (1S,2R-enantiomer) impurity is 0.5%. The established method was authenticated as per ICH guidelines in respect of precision, accuracy, sensitivity, linearity, specificity, ruggedness, and robustness. The minimum quantity of the sample required for detection (LOD) was observed at 0.282 μg per mL and similarly the quantifying sample (LOQ) was observed to be 0.896 μg per mL. Conclusion The proposed normal phase-HPLC method that can quantify (1S,2R-enantiomer) impurity in Bortezomib lyo injection formulation at trace level concentration has been urbanized and authenticated as per ICH guidelines. The effectiveness of the technique was ensured by the specificity, exactitude, linearity, and accuracy. Hence, the method well suit for their intended purposes and can be successfully useful for regular analysis in laboratories and is suitable for the quality control.https://doi.org/10.1186/s43094-020-00157-4(1S,2R-enantiomer) ImpurityBortezomibValidationLimit of quantitation
collection DOAJ
language English
format Article
sources DOAJ
author Sanni Babu Najana
Hari Babu Bollikolla
spellingShingle Sanni Babu Najana
Hari Babu Bollikolla
Determination of enantiomer impurity in Bortezomib lyo injection formulation by using normal-phase liquid chromatography
Future Journal of Pharmaceutical Sciences
(1S,2R-enantiomer) Impurity
Bortezomib
Validation
Limit of quantitation
author_facet Sanni Babu Najana
Hari Babu Bollikolla
author_sort Sanni Babu Najana
title Determination of enantiomer impurity in Bortezomib lyo injection formulation by using normal-phase liquid chromatography
title_short Determination of enantiomer impurity in Bortezomib lyo injection formulation by using normal-phase liquid chromatography
title_full Determination of enantiomer impurity in Bortezomib lyo injection formulation by using normal-phase liquid chromatography
title_fullStr Determination of enantiomer impurity in Bortezomib lyo injection formulation by using normal-phase liquid chromatography
title_full_unstemmed Determination of enantiomer impurity in Bortezomib lyo injection formulation by using normal-phase liquid chromatography
title_sort determination of enantiomer impurity in bortezomib lyo injection formulation by using normal-phase liquid chromatography
publisher SpringerOpen
series Future Journal of Pharmaceutical Sciences
issn 2314-7253
publishDate 2021-01-01
description Abstract Background A highly stereo-specific liquid chromatographic technique was built up and authenticated to quantify the (1S,2R-enantiomer) impurity in Bortezomib lyo injection formulation. The separation was achieved on Chiral Pak ID-3 (3 μm, 4.6 × 250 mm) column (“amylose-based 3-chlorophenylcarbamate” chiral stationary phase) through a movable segment consisting of n-heptane, 2-propanol, ethyl alcohol, and TFA (82:15:3:0.1, v/v/v/v) at a flow rate of 0.6 mL/min. Column temperature preserved 25 °C, injection level 20 μL, sample cooler temperature ambient, and detection wavelength 270 nm. Results The retention time of (1S,2R-enantiomer) impurity and Bortezomib was determined 10.57 and 17.98 min, respectively. The resolution between (1S,2R-enantiomer) impurity and Bortezomib was found to be 4.2. The acceptance limit of the (1S,2R-enantiomer) impurity is 0.5%. The established method was authenticated as per ICH guidelines in respect of precision, accuracy, sensitivity, linearity, specificity, ruggedness, and robustness. The minimum quantity of the sample required for detection (LOD) was observed at 0.282 μg per mL and similarly the quantifying sample (LOQ) was observed to be 0.896 μg per mL. Conclusion The proposed normal phase-HPLC method that can quantify (1S,2R-enantiomer) impurity in Bortezomib lyo injection formulation at trace level concentration has been urbanized and authenticated as per ICH guidelines. The effectiveness of the technique was ensured by the specificity, exactitude, linearity, and accuracy. Hence, the method well suit for their intended purposes and can be successfully useful for regular analysis in laboratories and is suitable for the quality control.
topic (1S,2R-enantiomer) Impurity
Bortezomib
Validation
Limit of quantitation
url https://doi.org/10.1186/s43094-020-00157-4
work_keys_str_mv AT sannibabunajana determinationofenantiomerimpurityinbortezomiblyoinjectionformulationbyusingnormalphaseliquidchromatography
AT haribabubollikolla determinationofenantiomerimpurityinbortezomiblyoinjectionformulationbyusingnormalphaseliquidchromatography
_version_ 1724342097788534784